Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Coinbase Global, Inc. (COIN) vs ResMed Inc. (RMD) Price & Performance

Coinbase Global, Inc.Trade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Coinbase Global, Inc. vs ResMed Inc. — how do they compare? Coinbase Global, Inc. trades at $148.04 (market cap $39.20B), while ResMed Inc. trades at $223.87 (market cap $32.61B). The key difference: Coinbase Global, Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.17% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals.

COINRMD
Market Cap
$39.20B$32.61B
Sector
TechnologyHealth
52-Week High
$387.27$293.73
52-Week Low
$141.09$182.82
Enterprise Value
$36.85B$31.97B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Coinbase Global, Inc.

COIN stock trades at $148.68, down 3.2% in the last session amid bearish technical signals and recent earnings misses. The company reported Q2 2026 revenue and EPS below expectations, marking the third consecutive quarterly loss despite achieving record 10.3% global trading volume share. Analyst sentiment remains mixed with 55% buy ratings but a Zacks strong sell designation on August 6, 2026. Technical indicators show bearish momentum with support at $141 and resistance at $152.

The outlook remains challenging with projected 2026 revenue decline to $6.3B and net loss of $988M. While the company maintains strong cash flow from operations ($2.4B in 2025) and is expanding into AI payment solutions, persistent earnings misses and crypto market volatility pose significant risks. The consensus price target of $207.20 suggests 39% upside potential if execution improves.

ResMed Inc.

ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.

The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Coinbase Global, Inc.

Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.

Read more on COIN

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD